Received: 12 January 2021
Accepted: 30 March 2021
First Online: 12 April 2021
: This study was conducted in compliance with the principles of the Declaration of Helsinki. The study protocol and the informed consent was reviewed and approved by the Institutional Review Board Ethics Committee of the Bavarian State Medical Association (Bayrische Landesärztekammer), Munich, Germany (no. 13104 from November 21, 2013). All study participants provided informed written consent prior to study enrolment. This non-interventional study was further registered at the Paul-Ehrlich-Institute, Langen, Germany (Registration Nr: NIS#255, ExternalRef removed).
: Not applicable.
: Niels Teich has served as a speaker, a consultant and/or an advisory board member for AbbVie, Biogen, Falk Foundation, Janssen, MSD, Norgine, Takeda, Tillotts, Vifor and has received research funding from Ferring Arzneimittel GmbH; Harald Grümmer has received personal fees from MSD and AbbVie; Eric Jörgensen has received personal fees from MSD, Thomas Liceni has received personal fees from MSD, Frank Holtkamp-Endemann has received personal fees from MSD, Tim Fischer and Susanne Hohenberger are employees of MSD Sharp & Dohme GmbH. All authors certify that they have no financial interests that are relevant to the content of this article.